Item 2.02. Results of Operations and Financial Condition. On November 10, 2026, Harvard Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the three and nine months ended September 30, 2026, and the details of a related conference call to be held at 8:00 AM ET on November 10, 2026. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.…
Filed Nov 10, 2026Accepted Nov 10, 2026, 7:00 AM ESTCIK 1123494Accession 0001171843-26-007308
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On November 10, 2026, Harvard Bioscience, Inc. (the “Company”)
issued a press release announcing financial results for the three and nine months ended September 30, 2026, and the details of a related
conference call to be held at 8:00 AM ET on November 10, 2026. The press release is furnished as Exhibit 99.1 and incorporated herein
by reference.
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached
hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.